I diopathic pulmonary arterial hypertension (PAH) is a fatal and progressive disease. Sustained pulmonary vasoconstriction and concentric pulmonary artery wall thickening are the primary causes of the elevated pulmonary vascular resistance and pulmonary arterial pressure in patients with idiopathic PAH. An increase in cytosolic free Ca 2+ concentration ([Ca 2+ ] cyt ) in pulmonary artery smooth muscle cells (PASMCs) is a major trigger for pulmonary vasoconstriction and an important cause for pulmonary vascular remodeling via stimulation of PASMC proliferation and inhibition of PASMC apoptosis. The current treatment for PAH is mainly based on the correction of increased ratio of circulating vasoconstrictors (eg, endothelin) to vasodilators (eg, prostacyclin and nitric oxide) by blocking endothelin receptors, increasing circulating prostacyclin or orally intaking prostacyclin analog, inhaling nitric oxide (NO), stimulating soluble guanylate cyclase or inhibiting phosphodiesterase.
I diopathic pulmonary arterial hypertension (PAH) is a fatal and progressive disease. Sustained pulmonary vasoconstriction and concentric pulmonary artery wall thickening are the primary causes of the elevated pulmonary vascular resistance and pulmonary arterial pressure in patients with idiopathic PAH. An increase in cytosolic free Ca 2+ concentration ([Ca 2+ ] cyt ) in pulmonary artery smooth muscle cells (PASMCs) is a major trigger for pulmonary vasoconstriction and an important cause for pulmonary vascular remodeling via stimulation of PASMC proliferation and inhibition of PASMC apoptosis. The current treatment for PAH is mainly based on the correction of increased ratio of circulating vasoconstrictors (eg, endothelin) to vasodilators (eg, prostacyclin and nitric oxide) by blocking endothelin receptors, increasing circulating prostacyclin or orally intaking prostacyclin analog, inhaling nitric oxide (NO), stimulating soluble guanylate cyclase or inhibiting phosphodiesterase. 1 The mortality, however, remains high in patients with idiopathic PAH. It is thus important to define precise mechanisms involved in PASMC contraction, proliferation, and apoptosis, identify novel therapeutic targets and develop new and effective therapeutic interventions for PAH. One of the potential pathogenic mechanisms for PAH for developing novel therapies is the enhanced intracellular Ca 2+ signaling in PAH-PASMCs, which not only induces PASMC contraction and migration but also stimulates PASMC proliferation and inhibits PASMC apoptosis.
In addition to causing PASMC contraction and pulmonary vasoconstriction, a rise in [Ca 2+ ] cyt in PASMC can activate transcription factors and signal transduction proteins essential for cell proliferation and migration. [2] [3] [4] [5] [6] Removal or chelation of extracellular free Ca 2+ inhibits PASMC proliferation and ] cyt in Human PASMC 519 migration, indicating that an increase in [Ca 2+ ] cyt because of Ca 2+ influx is a requisite for PASMCs to contract, proliferate, and migrate. 7, 8 We have previously reported that the resting [Ca 2+ ] cyt in PAH-PASMCs is significantly higher than in normal PASMCs, whereas receptor-operated Ca 2+ entry and store-operated Ca 2+ entry (SOCE) are both enhanced in PAHPASMCs compared with normal PASMCs. 6, [9] [10] [11] The enhanced receptor-operated Ca 2+ entry and SOCE have been demonstrated to result, at least partially, from upregulated protein expression and enhanced function of the transient receptor potential channels (eg, TRPC6/C3/C1) and Orai channels (Orai1/2). [12] [13] [14] [15] [16] Tight control of the resting [Ca 2+ ] cyt is vital in maintaining PASMC function and regulating PASMC contraction, proliferation, and apoptosis. 10, 17 Sustained and prolonged increase of the resting [Ca 2+ ] cyt to an abnormal level has been implicated in many neurological and cardiovascular diseases. 18, 19 STIM1 (stromal interaction molecule 1) protein is a Ca 2+ sensor expressed in the endoplasmic (ER) or sarcoplasmic (SR) reticulum membrane in a variety of cell types. Depletion or reduction of Ca 2+ in the ER/SR results in dissociation of Ca 2+ from the EF domain of STIM1, leading to STIM1 dimerization and translocation to the puncta area to recruit Orai1 proteins in the plasma membrane (PM) to form SOC and inducing SOCE. 20 STIM2 structurally shares significant homology with STIM1, the major differences between STIM2 and STIM1 are in the EF domain, 21 ] cyt or recruiting or gating Orai1 (and other SOC) at low concentrations of agonist stimulation. 22, 23 Through siRNA screening of human signaling proteome, STIM2 was identified as the most potent positive regulator of the resting [Ca 2+ ] cyt . 22 Thus, it has been demonstrated that STIM2 is more involved in regulating the resting [Ca 2+ ] cyt , whereas STIM1 is more involved in the regulation of SOCE. 22 The 
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Subjects
The diagnosis of PAH was established clinically in 5 patients by the National Institutes of Health PAH Registry with an average mean pulmonary arterial pressure of 56±5 mm Hg. Use of human pulmonary tissue and cell for these experiments was approved by The University of Arizona Institutional Review Board.
[Ca

2+
] cyt Measurement Fura-2 fluorescence was measured in PASMCs from normal subjects and patients with PAH as described previously, 26 with an NIS Elements 3.2 software on a Nikon inverted fluorescent microscope (Eclipse Ti-E; Nikon, Tokyo, Japan).
Drugs and Chemicals
Cyclopiazonic acid (Sigma-Aldrich) was prepared and aliquoted as stock solutions in DMSO and stored at −20°C until use.
Statistical Analysis
Data are expressed as the mean±SE. Statistical significance between 2 groups or among multiple groups was examined using Student t test or Scheffé test after 1-way ANOVA, respectively. Significant difference is expressed in the figure legends as *P<0.05, **P<0.01, and ***P<0.001.
An expanded materials and methods section is available in the online-only Data Supplement. 22 In small PA from normal subjects, we found that the protein expression of STIM2 was low in smooth muscle layer. In contrast, in PAs from patients with PAH, the protein expression of STIM2 was high in smooth muscle layer ( Figure S1A in the online-only Data Supplement). In isolated PASMCs, STIM2 exhibited significantly higher expression level in PAH patients than in normal subjects ( Figure 1C) . Similarly, STIM2 levels in PAs isolated from rats with monocrotaline-induced pulmonary hypertension (PH) and mice with hypoxia-induced PH, were both greater than in PAs from normal controls (data not shown and inhibiting PASMC apoptosis (eg, Bcl-2). 3, 4, 27 In addition, we also examined the effect of overexpressing STIM2 and enhancing [Ca 2+ ] cyt on the AKT signaling pathway, which has been shown to be Ca 2+ /CaM dependent. 28 The level of phosphorylated (p) CREB, STAT3, and AKT in PAH-PASMCs was significantly higher than in normal PASMCs under the resting condition ( Figure 2A ). The nuclear translocation of NFATc2 was detected (ie, activated NFATc2) in ≈40% PAH-PASMCs, whereas NFATc2 was mostly located in the cytoplasm (ie, inactive NFATc2) in >90% normal PASMCs ( Figure 2C ). Downregulation of STIM2 in PAH-PASMC with siRNA significantly reduced the level of pCREB, pSTAT3, and pAKT ( Figure 2B ) and decreased the nuclear translocation of NFATc2 ( Figure 2C ). We then overexpressed STIM2 in normal PASMCs to determine whether upregulation of STIM2 and increased resting [Ca 2+ ] cyt were sufficient to activate Ca 2+ -dependent signaling pathways. As shown in Figure 3A , overexpression of STIM2 in normal PASMCs increased pCREB, pSTAT3, and pAKT ( Figure 3A ) and enhanced NFATc2 nuclear translocation ( Figure 3C ). These results indicate that STIM2 is sufficient to increase phosphorylation of CREB, STAT3, and AKT, and activated NFATc2 in normal PASMC.
Results
Enhanced
To examine whether the STIM2-mediated activation of the signaling cascades results from the enhanced resting [Ca 2+ ] cyt , we repeated the experiments in the presence of EGTA (2 mmol/L) which reduces extracellular free [Ca 2+ ] to 500 nmol/L.
14 Reduction of extracellular Ca 2+ with EGTA (2 mmol/L for 24 hours) abolished the increase in the resting [Ca 2+ ] cyt induced by overexpression of STIM2 ( Figure 3D ), but didn't affect the transfection efficiency of STIM2 in normal PASMCs ( Figure 3B ). The level of pCREB, pSTAT3, and pAKT, and the nuclear translocation of NFATc2 in STIM2-transfected cells were significantly decreased when the cells were cultured in EGTA-containing media compared with the cells cultured in control (or EGTA-free) media ( Figure 3B ). These results suggest that STIM2 enhances phosphorylation of transcription factors CREB and STAT3, activates the AKT signaling cascade, and induces NFAT nuclear translocation by increasing the resting [Ca 2+ ] cyt in human PASMCs.
Upregulation of STIM2 Enhances PASMC Proliferation
It has been demonstrated that activated CREB, STAT3, AKT, and NFATc2 are involved in stimulating PASMC proliferation.
2-4 Upregulation of STIM2 in normal PASMCs significantly increased cell proliferation, determined by measuring 5-ethynyl-2-deoxyuridine incorporation or DNA synthesis, in comparison to cells transfected with an empty vector ( Figure 4A ); whereas downregulation of STIM2 in PAH-PASMCs with siRNA significantly decreased 5-ethynyl-2-deoxyuridine incorporation ( Figure 4B ). Furthermore, overexpression of STIM2 in normal PASMCs considerably increased the cell proliferation marker Ki67; whereas downregulation of STIM2 with siRNA in PAH-PASMCs decreased Ki67 ( Figure 4C ). These results suggest that upregulation of STIM2 is sufficient to enhance cell proliferation in normal PASMCs and necessary for the enhanced cell proliferation in PAH-PASMCs.
Upregulation of STIM2 Inhibits PASMC Apoptosis by Increasing Bcl-2/Bax Ratio
Bcl-2, an antiapoptotic protein, and Bax, a proapoptotic protein, both play an important role in regulating apoptosis in PASMCs. NFATc2 activation has been shown to contribute to Bcl-2 upregulation in PASMCs from idiopathic patients with PAH. 27 Our study showed that NFATc2 was more activated in PAH-PASMCs than in normal PASMCs ( Figures 2C and 3C) ] cyt affects PASMC apoptosis via NFATregulated Bcl-2 protein expression, we first compared Bcl-2 (and Bax) expression level and the Bcl-2/Bax ratio in normal and PAH PASMCs. The protein expression of Bcl-2 in PAH-PASMCs was significantly higher than in normal PASMCs, whereas the protein level of Bax was markedly lower in PAH-PASMCs than in normal PASMCs. Thus, the Bcl-2/Bax ratio was substantially higher in PAH-PASMCs than in normal PASMCs ( Figure 5A ). Furthermore, knockdown of STIM2 in PAH-PASMCs increased the percentage of TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling)-positive cells compared with PAHPASMCs treated with control-siRNA ( Figure 5B ), which was due apparently to the decreased Bcl-2/Bax ratio ( Figure 5C ). Reduction of extracellular Ca 2+ with EGTA also significantly decreased the protein level of Bcl-2 in PAH-PASMCs, resulting in the decrease of the Bcl-2/Bax ratio ( Figure 5D ). These results further support the hypothesis that the STIM2/Ca 2+ /NFATc2/ Bal-2 pathway plays an essential role in the regulation of apoptosis in PASMC and upregulation of STIM2 is one of the important contributors to inhibit PAH-PASMC apoptosis.
STIM2 Clusters Are Increased in PAH-PASMC
Translocation of polymerized STIM2 to the ER/SR-PM junctions develops STIM2 clusters that recruit Orai to form SOC inducing SOCE. 23 Under the resting condition, there were no or very few STIM2 clusters and STIM2-Orai1 colocalization in normal PASMCs; however, there were more STIM2 clusters and STIM2-Orai1 colocalization in PAH-PASMCs where STIM2 expression was upregulated ( Figure 6B ). Passive depletion of Ca 2+ from intracellular Ca 2+ stores (or SR) using cyclopiazonic acid, an SR Ca 2+ -pump inhibitor, further induced STIM2 clusters and enhanced STIM2-Orai1 colocalization in both normal and PAH-PASMCs ( Figure 6A ). These results indicate that upregulated STIM2 in PAH-PASMCs can (1) translocate to the ER/SR-PM junctions to recruit and interact with Orai1 channels to mediate Ca 2+ influx without store depletion, and (2) further translocate to the puncta area to enhance SOCE when intracellular stores are depleted.
It has been reported that a STIM2 preprotein is involved in STIM2-mediated and store-independent Ca 2+ influx. 24 Our
Western blot data showed that there were 2 closely located bands of STIM2 in both normal and PAH-PASMCs; the upper band could be the STIM2 preprotein or the glycosylated STIM2. Using deglycosylation enzyme PNGaseF, we were able to eliminate the upper band indicating that the observed 2 bands of STIM2 were STIM2 and the glycosylated STIM2 rather than STIM2 and the STIM2 preprotein ( Figure 6C ). 
Discussion
The results of this study indicate that (1) 
STIM2-Mediated Regulation of Intracellular Ca
2+
Homeostasis
As an ER/SR Ca 2+ sensor, the commonly reported function of STIM2 is its contribution to the initiation and regulation of SOCE. Enhanced SOCE due partially to upregulation of STIM proteins as well as Orai and transient receptor potential channels has been implicated in stimulating PASMC proliferation, phenotypic transition of contractile PASMC to proliferative PASMC, and the development of PAH. 13, 29 There are at least 2 STIM2 splice variants, STIM2.1 and STIM2.2, which are both expressed in PASMCs. Functional studies have revealed that STIM2.2 promotes SOCE, whereas STIM2.1 inhibits SOCE. 30, 31 The effect of STIM2 overexpression on SOCE varies significantly among different cell types; for example, overexpression of STIM2 in T cells and fibroblasts enhances SOCE, 32 whereas overexpression of STIM2 in HEK293 cells and PC12 cells actually inhibits SOCE. 33 Nonetheless, overexpression of STIM2 has consistently produced a significant enhancement in the resting [ -responsive transcription factors (eg, CREB, STAT3, and NFAT; Figures 1 through 3 ). An interesting finding from this study is that STIM2-associated increase in the resting [Ca 2+ ] cyt in human PASMCs also results in the rise of Bcl-2/Bax ratio, which is potentially and partially responsible for the apoptosis resistance of PAH-PASMCs. 27, 34 The observations from this study imply that downregulation or inhibition of STIM2, more specifically, STIM2.2, may potentially be a critical target to develop novel drugs to inhibit the development of pulmonary arterial remodeling and regress the remodeled pulmonary arteries responsible for the elevated pulmonary vascular resistance in patients with PAH.
STIM2-Associated Increase in the Resting [Ca 2+ ] cyt and PASMC Proliferation
There are at least 4 steps in the cycle that are sensitive to Ca 2+ and its downstream signaling cascades: the transition from the G 0 to G 1 phase, the transition from the G 1 to S phase, the transition from the G 2 to M phase, and the whole M phase (or mitosis). 35 ] cyt induces PASMC proliferation by initiating or promoting the cell cycle via activation of proproliferative signaling cascades and transcription factors. In this study, we provide substantial evidence that STIM2-associated increase in the resting [Ca 2+ ] cyt in PASMCs enhances phosphorylation of AKT, STAT3, and CREB, promotes the nuclear translocation of NFAT, and stimulates cell proliferation (determined by 5-ethynyl-2-deoxyuridine incorporation and expression of Ki67). STIM2 is sufficient to increase the resting [Ca 2+ ] cyt and promote cell proliferation in normal PASMCs, whereas upregulated STIM2 is necessary for the enhanced resting [Ca 2+ ] cyt and augmented cell proliferation in PAH-PASMCs. Specific downregulation and inhibition of STIM2 or STIM2.2 would potentially be an excellent strategy to develop novel therapies for the treatment of PAH and other forms of PH with severe pulmonary vascular remodeling.
The PI3K-AKT-mTOR signaling cascade is a critical intracellular pathway that regulates the cell cycle, protein expression, and cell proliferation. 36 Growth factor-mediated activation of GPCR (G-protein-coupled receptors; eg, CaSR and ET A receptors) and TKR (tyrosine kinase receptors; eg, PDGF receptors), along with an increase in [Ca 2+ ] cyt , can promote the production of PI3K 37 that subsequently activates or phosphorylates AKT and promotes the AKT/mTOR signaling and other AKT-dependent signaling pathways. In this study, we showed that STIM2-mediated increase in the resting 
2+
] cyt in Human PASMC 527 [Ca 2+ ] cyt in PAH-PASMCs (or in normal PASMCs transiently transfected with STIM2) was associated with significant phosphorylation of AKT. Phosphorylated AKT can further activate or phosphorylate CREB and mTOR, leading to cell proliferation and gene expression. It has been demonstrated that Ca 2+ / CaMK4 (CaM-dependent kinase 4) is also involved in activating AKT and thus promoting the AKT/mTOR signaling pathways to stimulate cell proliferation. 28 In addition to AKT, our data also indicated significant phosphorylation of STAT3 and nuclear translocation of NFAT in PAH-PASMCs in which STIM2 was upregulated in comparison to normal PASMCs. The JAK/STAT3 signaling cascade is another important intracellular signaling pathway that mediates cytokine-induced and mitogen-induced cell proliferation. 
STIM2-Associated Increase in the Resting [Ca
2+
] cyt and PASMC Apoptosis Bcl-2, an antiapoptosis protein that mediates antiapoptotic effect on a variety of cells, has been reported to be highly expressed in PASMCs isolated from patients with idiopathic PAH. 27 The data from this study not only confirmed the upregulation of Bcl-2 or increase of the Bcl-2/Bax ratio in PAHPASMCs but also revealed that the STIM2-mediated increase of the resting [Ca 2+ ] cyt is one of the causes for the upregulated Bcl-2 or increased Bcl-2/Bax ratio. The STIM2-associated increase in the Bcl-2/Bax ratio would ultimately contribute to the resistance of PAH-PASMCs to apoptosis. 34 Excessive activation of NFAT or enhanced nuclear translocation of NFAT because of elevated resting [Ca 2+ ] cyt is considered as the driving force behind in regulating Bcl-2 expression. 27 In lung cancer cells, ATP-induced increase in [Ca 2+ ] cyt has been shown to upregulate Bcl-2 expression as well. 38 These observations indicate that intracellular Ca 2+ is an important regulator of Bcl-2 expression; an increase in [Ca 2+ ] cyt would upregulate Bcl-2 expression via activation of NFAT and other Ca 2+ /CaMsensitive signaling cascades, which result in an antiapoptotic effect on PASMCs and cancer cells.
Increased PASMC proliferation and decreased PASMC apoptosis in the pulmonary arterial wall both contribute to the development and progression of pulmonary vascular wall thickening, a major cause for the elevated pulmonary vascular resistance and pulmonary arterial pressure in patients with PAH and animals with several PH. The indirect antiapoptotic effect of STIM2, by increasing the resting [Ca 2+ ] cyt , activation of NFAT and upregulation of Bcl-2 in PASMCs, suggests a new pathogenic role of the STIM2-mediated Ca 2+ signaling in the development of pulmonary vascular remodeling in patients with PAH. Given the previous observation that only STIM2 protein level was increased in PASMCs from patients with PAH (but not STIM1), 12 we believe that upregulated STIM2 may play an important pathogenic role in PAH by stimulating PASMC proliferation and inhibiting PASMC apoptosis.
STIM2 Clusters and Activates Orai1 Channels Under Resting Conditions in PAH-PASMCs
We observed that, under resting conditions or when intracellular stores were not passively or actively depleted or reduced, more STIM2 clusters colocalized with Orai1 near the PM area in PAH-PASMCs than in normal PAMSCs ( Figure 6B) A cytoplasmic STIM2 preprotein that cannot target ER/ SR has been discovered recently to play an important role in recruiting and activating Orai1 channels in a store-independent manner. 24 In our Western blot experiments, we often detected an upper band in both normal and PAH PASMCs ( Figure 6C ), which is similar to the STIM2 preprotein band as indicated by other investigators. 24 However, treatment of with PNGaseF, an enzyme that catalyzes the cleavage of an internal glycoside bond in an oligosaccharide, abolished the upper STIM2 band, indicating that the upper STIM2 band is the glycosylated STIM2 band rather than the STIM2 preprotein band. It is thus possible that STIM2 preprotein may express in human PASMCs at a very low level and its functional role is unclear. Furthermore, it also remains unclear whether glycosylation of STIM2 contributes to enhancing its function to cluster and recruit Orai1 proteins in the PM.
In summary, this study provides compelling evidence that STIM2, a Ca 2+ sensor expressed in the ER/SR membrane, plays an important role in regulating the resting [ ] cyt and activated Ca 2+ -sensitive signaling pathways (eg, AKT/mTOR, AKT/CREB, STAT3, and NFAT), contributes to enhancing PASMC proliferation and inhibiting PASMC apoptosis and ultimately lead to the development and progression of pulmonary vascular remodeling in PAH. Pulmonary vascular smooth muscle STIM2 is potentially a promising drug target for developing novel therapies for PAH and other forms of PH.
Limitations
For the in vitro experiments, we used PASMCs isolated from a limited number of donors (n=3 normal subjects) and patients (n=5 patients with PAH). The significance of our findings thus needs to be further confirmed by examining PASMCs from more patients with PAH and patients with other forms of PAH. Also, we used primary cultured PAMSCs, which might undergo phenotypic changes to unmask certain pathogenic or pathological characteristics. We will conduct in vivo experiments using animal models to confirm the findings shown in this study and will investigate whether smooth muscle-specific knockout of STIM2 ameliorates the development and progression of experimental PH in animals.
Sustained pulmonary vasoconstriction and concentric pulmonary vascular wall thickening both directly contribute to the elevated pulmonary vascular resistance and, subsequently, increased pulmonary arterial pressure and right heart failure in patients with PAH. Medial hypertrophy caused by excessive PASMC proliferation and attenuated PASMC apoptosis in distal vessels account for excessive pulmonary vascular remodeling in patients with PAH. Identifying the pathogenic mechanisms involved in enhanced PASMC proliferation, and impaired PASMC apoptosis is important to develop effective therapies for PAH. This study suggests that upregulated STIM2 in PASMCs is potentially a critical drug target for developing novel therapies to treat PAH or PH in general.
Perspectives
The current study identifies STIM2 as one of the major regulators that increases the resting [Ca 2+ ] cyt in PASMCs from patients with PAH. The STIM2-associated rise in the resting [Ca 2+ ] cyt stimulates PASMC proliferation by activating AKT, STAT3, and NFAT signaling pathways and inhibits PASMC apoptosis by upregulating Bcl-2. Inhibition or downregulation of STIM2 may restore the pathogenic rise in the resting [Ca 2+ ] cyt in PASMCs, and attenuate or reverse pulmonary vascular remodeling in PAH. The findings of this study, therefore, warrant further translational studies to exploit STIM2 as a drug target for developing novel therapies for PAH.
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